2
CDK/cyclin | Deficiency in some kind of cancers | Over-expression in some kind of cancers |
CyclinD1 | B-cell malignancies and many kinds of solid tumors, including breast, bladder, lung, esophageal, and hepatocellular carcinomas | |
CyclinD2 | Pancreatic, breast, and prostate cancers | Ovarian and testicular tumors |
CyclinD3 | Glioblastomas, renal cell carcinomas, pancreatic adenocarcinomas, and several B-cell malignancies | |
CDK4 | Gliomas, sarcomas, and breast and cervical carcinomas | |
CDK6 | Gliomas and lymphoid tumors | |
Cyclin E | Uterine, pancreatic, and ovarian cancers, NSCLC, leukemias, lymphomas, and osteosarcoma | |
Cyclin A | Thyroid carcinoma, melanoma, breast cancer, lung, osteosarcoma, and ovarian and endometrial carcinomas | |
CDK2 | Sarcomas, melanoma, osteosarcoma, and pancreatic, ovarian, breast, lung, and thyroid carcinomas | |
Cyclin B | Breast, colon, prostate, and thyroid carcinomas and NSCLC | |
CDK1 | Lymphoma, advanced melanoma, and lung cancer |
CDK, cyclin-dependent kinases. NSCLC, non-small cell lung cancer.